Abbott Laboratories (ABT)

43.64
0.01 0.02
NYSE : Health Care
Prev Close 43.65
Open 43.67
Day Low/High 43.50 / 43.75
52 Wk Low/High 36.76 / 45.84
Volume 6.01M
Avg Volume 7.57M
Exchange NYSE
Shares Outstanding 1.73B
Market Cap 75.69B
EPS 0.90
P/E Ratio 61.69
Div & Yield 1.06 (2.40%)

Latest News

Berkshire Hathaway, Southwest, Alaska Air: 'Mad Money' Lightning Round

Berkshire Hathaway, Southwest, Alaska Air: 'Mad Money' Lightning Round

Jim Cramer says he respects Buffett's judgment. Cramer's also bullish on some airline stocks.

Vive la U.S. Earnings: Cramer's 'Mad Money' Recap (Monday 4/24/17)

Vive la U.S. Earnings: Cramer's 'Mad Money' Recap (Monday 4/24/17)

Jim Cramer says a rally on French election results is fine, but don't forget great U.S. corporate earnings and merger activity.

Market Rally Rates a Meh

There is very little upside mo-mehn-tum.

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.

S&P 500, Dow End at Session Lows After IBM Disappointment, Crude Slump

S&P 500, Dow End at Session Lows After IBM Disappointment, Crude Slump

Earlier market optimism faded as Wednesday wore on and a financials rally gave way to a selloff in Dow Jones Industrial Average component IBM and energy shares.

S&P 500 in Red as Energy's Slide Counters Morgan Stanley Gains

S&P 500 in Red as Energy's Slide Counters Morgan Stanley Gains

The S&P 500 hugs the flatline on Wednesday afternoon as a selloff in crude oil prices and energy shares counters better-than-expected earnings from Morgan Stanley.

Midday Report: Morgan Stanley Boosts Financials; IBM Drags Dow Into Red

Midday Report: Morgan Stanley Boosts Financials; IBM Drags Dow Into Red

Earnings take center stage again with a disappointment from IBM and a better-than-expected performance from Morgan Stanley dividing markets.

IBM Weighs on Dow, Morgan Stanley Gives Financials a Boost

IBM Weighs on Dow, Morgan Stanley Gives Financials a Boost

Earnings drive markets again on Wednesday with IBM dragging on the Dow Jones Industrial Average and Morgan Stanley driving financials, and broader markets, higher.

Market Recon: The Banks Trade Will Become a Yield Curve Watch

Market Recon: The Banks Trade Will Become a Yield Curve Watch

It really is that simple. Mr. and Ms. Market no longer trust the outlook for domestic economic growth.

Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition

Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition

Pfizer launched a Remicade biosimilar in November.

JNJ Shares Tick Up as Investors Eye Results for Three Business Lines

JNJ Shares Tick Up as Investors Eye Results for Three Business Lines

JNJ has been busy integrating newly acquired businesses.

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.

Stocks That Are Changing Direction

Stocks That Are Changing Direction

These charts are showing bullish or bearish reversals.

Alere Stock Surging on Latest Abbott Agreement

Alere Stock Surging on Latest Abbott Agreement

Abbott will now pay a lower price to acquire Alere.

Cramer: These Stocks Look Like 'Easy Pickings'

Cramer: These Stocks Look Like 'Easy Pickings'

From Aetna to United Technologies, these names are hot.

Cramer: The Best Performers Show No Signs of Letting Up

Cramer: The Best Performers Show No Signs of Letting Up

Their overseas business has been carrying them.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Can the Repeal of the Fiduciary Rule Harm Your Annuities Investments?

Can the Repeal of the Fiduciary Rule Harm Your Annuities Investments?

Annuities are in the news as Trump's appointee to head the Department of Labor spars with Sen. Warren. Here's what investors need to know.

Must-Own Dividend Dates for April

Mark your calendars!

Mylan Hit After Abbott Dumps Shares

Mylan Hit After Abbott Dumps Shares

The company decreased its 13% stake in Mylan Friday.

Can Abbott Outperform Despite Alere?

Can Abbott Outperform Despite Alere?

Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.

Abbott Labs Is Set to Go Substantially Higher

Abbott Labs Is Set to Go Substantially Higher

Here are the levels to watch and act on.

Late-Breaking Data Shows The CardioMEMS HF System Is Effective In Reducing Heart Failure Hospitalizations And Cost Of Care

Late-Breaking Data Shows The CardioMEMS HF System Is Effective In Reducing Heart Failure Hospitalizations And Cost Of Care

PRESENTED AT ACC AND PUBLISHED IN JOURNAL OF AMERICAN COLLEGE OF CARDIOLOGY, THE CARDIOMEMS™ HF SYSTEM OFFERS SUSTAINED BENEFITS FOR PATIENTS SUFFERING FROM SYMPTOMATIC HEART FAILURE